RA Capital Management, L.P.
About RA Capital Management, L.P.’s 13F portfolio
RA Capital Management, L.P. is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , RA Capital Management, L.P. reported $11.5B across 84 US-listed positions (). Its largest position is ASCENDIS PHARMA A/S (ASND) at 24% of the reported book, and its ten biggest holdings make up 60% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ASND ASCENDIS PHARMA A/S | — — | 24% | 10.3M | $2.7B |
| 2 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 6.9% | 28.9M | $791.9M |
| 3 | NASDAQ: RYTM RHYTHM PHARMACEUTICALS INC | — — | 6.4% | 6.7M | $740.2M |
| 4 | NASDAQ: PCVX VAXCYTE INC | — — | 5.8% | 11.5M | $667.0M |
| 5 | NASDAQ: SION SIONNA THERAPEUTICS INC | — — | 3.8% | 9.9M | $435.7M |
| 6 | NASDAQ: TYRA TYRA BIOSCIENCES INC | — — | 3.4% | 12.2M | $389.6M |
| 7 | NASDAQ: EWTX EDGEWISE THERAPEUTICS INC | — — | 3.0% | 8.4M | $341.0M |
| 8 | NASDAQ: NAMS NEWAMSTERDAM PHARMA CO NV | — — | 2.8% | 9.6M | $323.7M |
| 9 | NASDAQ: COAG HEMAB THERAPEUTICS HOLDINGS | — — | 2.5% | 7.8M | $286.8M |
| 10 | NASDAQ: SEPN SEPTERNA INC | — — | 2.0% | 7.0M | $234.3M |
| 11 | NASDAQ: BCAX BICARA THERAPEUTICS INC | — — | 1.9% | 7.3M | $215.4M |
| 12 | NASDAQ: MLYS MINERALYS THERAPEUTICS INC | — — | 1.8% | 7.7M | $207.6M |
| 13 | NASDAQ: GHRS GH RESEARCH PLC | — — | 1.8% | 7.6M | $205.3M |
| 14 | NASDAQ: IRON DISC MEDICINE INC | — — | 1.6% | 2.5M | $179.2M |
| 15 | NASDAQ: SGP SPYGLASS PHARMA INC | — — | 1.6% | 8.0M | $178.6M |
| 16 | NASDAQ: ARTV ARTIVA BIOTHERAPEUTICS INC | — — | 1.5% | 18.0M | $174.2M |
| 17 | NASDAQ: JANX JANUX THERAPEUTICS INC | — — | 1.5% | 11.2M | $171.9M |
| 18 | NASDAQ: TSHA TAYSHA GENE THERAPIES INC | — — | 1.4% | 23.6M | $160.4M |
| 19 | NASDAQ: BCRX BIOCRYST PHARMACEUTICALS INC | — — | 1.4% | 15.8M | $158.3M |
| 20 | NASDAQ: WVE WAVE LIFE SCIENCES LTD | — — | 1.4% | 27.0M | $156.7M |
| 21 | NASDAQ: NUVL NUVALENT INC-A | — — | 1.3% | 1.2M | $153.9M |
| 22 | NASDAQ: ABVX ABIVAX SA-ADR | — — | 1.3% | 1.1M | $150.9M |
| 23 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | — — | 1.3% | 1.6M | $148.0M |
| 24 | NASDAQ: CLYM CLIMB BIO INC | — — | 1.3% | 11.3M | $147.4M |
| 25 | NASDAQ: SLDB SOLID BIOSCIENCES INC | — — | 1.0% | 12.0M | $120.2M |
Showing 1–25 of 84 positions on this page reported in this 13F.
- Healthcare87%
- Financial Services0.1%
- NewASNDASCENDIS PHARMA A/S—$2.7B
- NewPBLSPARABILIS MEDICINES INC—$791.9M
- NewCOAGHEMAB THERAPEUTICS HOLDINGS—$286.8M
- AddedARTVARTIVA BIOTHERAPEUTICS INC+82.2%$174.2M
- NewABVXABIVAX SA-ADR—$150.9M
- NewORKAORUKA THERAPEUTICS INC—$148.0M
- AddedSLDBSOLID BIOSCIENCES INC+28.9%$120.2M
- AddedZLABZAI LAB LTD-ADR+0.6%$109.1M
- AddedXNCRXENCOR INC+7.7%$84.9M
- NewNTLAINTELLIA THERAPEUTICS INC—$76.6M
- ReducedEWTXEDGEWISE THERAPEUTICS INC−19.5%$341.0M
- ReducedGHRSGH RESEARCH PLC−0.5%$205.3M
- ReducedNUVLNUVALENT INC-A−50.8%$153.9M
- ReducedGERNGERON CORP−32.9%$54.8M
- ReducedVORVOR BIOPHARMA INC−55.6%$44.2M
- ReducedAKTSAKTIS ONCOLOGY INC−12.6%$42.4M
- ReducedOVIDOVID THERAPEUTICS INC−2.0%$28.2M
- ReducedACETADICET BIO INC−21.1%$8.1M
- ReducedHOWLWEREWOLF THERAPEUTICS INC−64.3%$859K
- ReducedPTNPALATIN TECHNOLOGIES INC−11.3%$670K
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | ARTV ARTIVA BIOTHERAPEUTICS, INC. | 13D | 37.9% | 18.4M | Filed 23 JUL 2026 |
| 2 | CLYM Climb Bio, Inc. | 13D | 33.0% · 2 classes | 23.9M | Filed 09 NOV 2026 |
| 3 | PEPG PEPGEN INC. | 13D | 30.5% · 2 classes | 28.7M | Filed 17 NOV 2026 |
| 4 | ABOS ACUMEN PHARMACEUTICALS, INC. | 13D | 29.5% · 2 classes | 21.1M | Filed 17 MAR 2026 |
| 5 | ACRV ACRIVON THERAPEUTICS, INC. | 13D | 28.8% | 12.3M | Filed 23 APR 2026 |
| 6 | SGP SPYGLASS PHARMA, INC. | 13D | 24.1% | 8.0M | Filed 17 FEB 2026 |
| 7 | PBLS Parabilis Medicines, Inc. | 13D | 23.8% | 28.9M | Filed 18 JUN 2026 |
| 8 | SION SIONNA THERAPEUTICS, INC. | 13D | 22.6% · 2 classes | 10.1M | Filed 07 NOV 2025 |
| 9 | TYRA TYRA BIOSCIENCES, INC. | 13D | 21.2% · 2 classes | 12.3M | Filed 06 MAR 2026 |
| 10 | VOR VOR BIOPHARMA INC. | 13D | 19.9% · 2 classes | 12.9M | Filed 21 JUL 2026 |
| 11 | JANX JANUX THERAPEUTICS, INC. | 13D | 19.9% | 12.0M | Filed 10 MAR 2025 |
| 12 | WVE WAVE LIFE SCIENCES LTD. | 13D | 17.1% · 3 classes | 34.2M | Filed 17 APR 2026 |
| 13 | COAG Hemab Therapeutics Holdings, Inc. | 13G | 16.6% | 7.7M | Filed 11 MAY 2026 |
| 14 | BBTX Bambusa Therapeutics, Inc. | 13D | 14.6% | 7.4M | Filed 06 NOV 2026 |
| 15 | HOWL WEREWOLF THERAPEUTICS, INC. | 13D | 13.8% | 6.7M | Filed 06 NOV 2025 |
| 16 | LENZ LENZ THERAPEUTICS, INC. | 13D | 13.6% | 4.3M | Filed 07 NOV 2025 |
| 17 | SEPN SEPTERNA, INC. | 13D | 11.8% | 5.5M | Filed 14 AUG 2026 |
| 18 | BCAX BICARA THERAPEUTICS INC. | 13D | 11.5% | 7.3M | Filed 02 MAR 2026 |
| 19 | SPRY ARS PHARMACEUTICALS, INC. | 13D | 11.1% | 10.9M | Filed 01 OCT 2025 |
| 20 | GERN GERON CORPORATION | 13G | 9.9% · 2 classes | 66.5M | Filed 14 AUG 2026 |
| 21 | TSHA TAYSHA GENE THERAPIES, INC. | 13G | 9.9% · 2 classes | 32.8M | Filed 16 NOV 2026 |
| 22 | IVVD Invivyd, Inc. | 13G | 9.9% · 2 classes | 21.3M | Filed 29 AUG 2025 |
| 23 | PALI Palisade Bio, Inc. | 13G | 9.9% · 2 classes | 20.9M | Filed 16 NOV 2026 |
| 24 | IPSC Century Therapeutics, Inc. | 13G | 9.9% | 17.9M | Filed 16 JAN 2026 |
| 25 | RZLT Rezolute, Inc. | 13G | 9.9% | 15.3M | Filed 18 DEC 2025 |
Showing 1–25 of 80 disclosed stakes. 10 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading RA Capital Management, L.P.’s 13F portfolio
RA Capital Management, L.P.’s $11.5B 13F book is spread across 84 reported positions and is highly concentrated — its ten largest positions alone are 60% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are ASND, PBLS, RYTM, PCVX and SION, led by ASCENDIS PHARMA A/S (ASND) at 24% of the portfolio. The heaviest sector exposure is Healthcare (87%), then Financial Services (0%).
What RA Capital Management, L.P. changed last quarter
Between 2026-03-31 and Q2 2026, RA Capital Management, L.P. was roughly balanced between buying and selling: it opened 17 new positions and added to 10 more, while trimming 10 and closing 18 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ASCENDIS PHARMA A/S (ASND), and its biggest reduction was EDGEWISE THERAPEUTICS INC (EWTX).
What a 13F does and doesn’t reveal
A 13F captures only RA Capital Management, L.P.’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names RA Capital Management, L.P. is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. RA Capital Management, L.P.'s profile on this page is built directly from those filings.
How current is the 13F data on RA Capital Management, L.P.'s page?
It reflects RA Capital Management, L.P.'s most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When RA Capital Management, L.P. files its next quarterly report, this page refreshes automatically.
Can I see RA Capital Management, L.P.'s complete list of holdings?
This page highlights RA Capital Management, L.P.'s largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under RA Capital Management, L.P.'s filings.
Does a 13F show everything RA Capital Management, L.P. owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of RA Capital Management, L.P.'s book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why RA Capital Management, L.P. made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

